Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Exact Sciences Q2 2024 GAAP EPS $(0.09) Beats $(0.32) Estimate, Sales $699.264M Beat $690.003M Estimate

Author: Benzinga Newsdesk | July 31, 2024 04:06pm
Exact Sciences (NASDAQ:EXAS) reported quarterly losses of $(0.09) per share which beat the analyst consensus estimate of $(0.32) by 71.88 percent. This is a 80 percent increase over losses of $(0.45) per share from the same period last year. The company reported quarterly sales of $699.264 million which beat the analyst consensus estimate of $690.003 million by 1.34 percent. This is a 12.41 percent increase over sales of $622.093 million the same period last year.

Posted In: EXAS


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist